Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Prostatic Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Rectal Neoplasms 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Papillary Thyroid Microcarcinoma 1Pancreatic Neuroendocrine Tumors (pNET) 1Oropharyngeal Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Meningioma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1

Interventions

daratumumab 4Lenalidomide 3dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Dexamethasone 2Curcumin 2Calcium Dobesilate 2piperine 1isatuximab 1iberdomide 1Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Observation 1Melphalan 1Leflunomide 1IPH-2101 1Dietary Fiber 1Diet, Mediterranean 1Cholestyramine Resin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Watchful Waiting × 90 days × Clear all
NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
226 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡